Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: Association with progression and fludarabine-refractoriness

Blood

Volumn 118, Issue 26, 2011, Pages 6904-6908

  Rossi, Davide ^a   Bruscaggin, Alessio ^a   Spina, Valeria ^a   Rasi, Silvia ^a   Khiabanian, Hossein ^b   Messina, Monica ^b   Fangazio, Marco ^a   Vaisitti, Tiziana ^c   Monti, Sara ^a   Chiaretti, Sabina ^d   Guarini, Anna ^d   Del Giudice, Ilaria ^d   Cerri, Michaela ^a   Cresta, Stefania ^a   Deambrogi, Clara ^a   Gargiulo, Ernesto ^a   Gattei, Valter ^e   Forconi, Francesco ^f   Bertoni, Francesco ^g   Deaglio, Silvia ^c   Rabadan, Raul ^b   Pasqualucci, Laura ^b,h,i   Foà, Robin ^d   Dalla Favera, Riccardo ^b,h   Gaidano, Gianluca ^a   more..

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^f UNIVERSITY OF SIENA   (Italy)

^g ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^h NewYork Presbyterian Hospital   (United States)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUDARABINE; GENOMIC DNA; RIBONUCLEOPROTEIN; SF3B1 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CODON; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC REGULATION; HUMAN; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; SPLICEOSOME;

EID: 84255160977     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-373159     Document Type: Article

References (25)

1. Müller-Hermelink HK, Montserrat E, Catovsky D, Campo E, Harris NL, Stein H. Chronic lymphocytic leukemia/small lymphocytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:180-182.
2. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
3. Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011;117(12):3391-3401.
4. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med. 2005;352(8):804-815.
5. Kay NE, O'Brien SM, Pettitt AR, Stilgenbauer S. The role of prognostic factors in assessing 'high-risk'subgroups of patients with chronic lymphocytic leukemia. Leukemia. 2007;21(9):1885-1891. (Pubitemid 47299960)
6. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2010;2010:481-488.
7. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
8. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
9. Stein H, Warnke RA, Chan WC, Jaffe ES. Diffuse large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., eds. World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:233-237.
10. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
11. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916. (Pubitemid 32064784)
12. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res. 2009;15(3):995-1004.
13. Zenz T, Häbe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114(13):2589-2597.
14. Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts [published online ahead of print September 2, 2011]. Leukemia. doi:10.1038/leu.2011.232.
15. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;365(15):1384-1395.
16. Luke MM, Della Seta F, Di Como CJ, Sugimoto H, Kobayashi R, Arndt KT. The SAP, a new family of proteins, associate and function positively with the SIT4 phosphatase. Mol Cell Biol. 1996;16(6):2744-2755. (Pubitemid 26161278)
17. Wang C, Chua K, Seghezzi W, Lees E, Gozani O, Reed R. Phosphorylation of spliceosomal protein SAP 155 coupled with splicing catalysis. Genes Dev. 1998;12(10):1409-1414. (Pubitemid 28243626)
18. Das BK, Xia L, Palandjian L, Gozani O, Chyung Y, Reed R. Characterization of a protein complex containing spliceosomal proteins SAPs 49, 130, 145, and 155. Mol Cell Biol. 1999;19(10):6796-6802. (Pubitemid 29441863)
19. Wahl MC, Will CL, Lührmann R. The spliceosome: design principles of a dynamic RNP machine. Cell. 2009;136(4):701-718.
20. David CJ, Manley JL. Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 2010;24(21):2343-2364.
21. Ward AJ, Cooper TA. The pathobiology of splicing. J Pathol. 2010;220(2):152-163.
22. Andrade MA, Bork P. HEAT repeats in the Huntington's disease protein. Nat Genet. 1995;11(2):115-116.
23. Andrade MA, Perez-Iratxeta C, Ponting CP. Protein repeats: structures, functions, and evolution. J Struct Biol. 2001;134(2-3):117-131.
24. Kaida D, Motoyoshi H, Tashiro E, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol. 2007;3(9):576-583. (Pubitemid 47294395)
25. Corrionero A, Miñana B, Valcárcel J. Reduced fidelity of branch point recognition and alternative splicing induced by the antitumor drug spliceostatin A. Genes Dev. 2011;25(5):445-459.